Thread by @jonworth

OK, so next in the series of Jon looking at supply of each different COVID vaccine it's:

Novavax

This one is different to AZ, BioNTech, J&J etc., in that the EU has no APA with Novavax *yet*

Even that is somewhat confusing - Reuters reports that this is because Novavax is dragging its heels, citing production problems
reuters.com/article/health…

The UK meanwhile has a contract for 60 million doses
thesun.co.uk/news/14314756/…

As does the USA
cnbc.com/2020/07/07/us-…

Last week Novavax confirmed production is underway in Teeside in the UK, but the company was not willing to be drawn on supply numbers

gazettelive.co.uk/news/teesside-…

Based on the above two links, the details of the supply chain here are sketchy - there are plants in UK, CZ, US, India - but how this all fits together I cannot work out based on public sources

CZ factory is not enough for EU needs, according to Reuters

Meanwhile Phase III in UK is complete, but when MHRA will approve Novavax is also so far unknown

This piece also examines its effectiveness targeting the B.1.351 variant

fiercebiotech.com/biotech/novava…

And this adds further detail about the approvals in the USA that could take longer

Consensus appears to be that the UK is going to be first to approve this, whenever that happens though

medicalxpress.com/news/2021-03-n…

It strikes me that it's hard to draw any solid conclusions here, other than that the EU is definitely not going to be at the front of the queue to get any Novavax supplies

Is that going to matter?

It's hard to know. *If* this works according to the best case scenario it could be an excellent call made by UK. If instead approval drags and supply is slow, and BioNTech supply ramps up sooner instead... maybe the EU might not be so bothered

/ends